You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Bemarituzumab

From EverybodyWiki Bios & Wiki

Bemarituzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetFGFR2
Clinical data
ATC code
  • none
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}

Bemarituzumab (INN[1]) is a monoclonal antibody directed against fibroblast growth factor receptor 2b.[2][3] It is being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.

This drug is being developed by Five Prime Therapeutics, Zai Lab Limited. As of 2018, bemarituzumab is undergoing Phase III trials.[4][5]

References[edit]

  1. World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. "Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers". Business Wire. 2018-09-10.
  3. "Bemarituzumab". National Cancer Institute.
  4. "Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - BioSpace".
  5. "Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - BioSpace".


This article "Bemarituzumab" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Bemarituzumab. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.